Methods and compositions for inducing hematopoietic cell differentiation
AssigneeFate Therapeutics, Inc.
InventorsBahram Valamehr, Raedun Clarke
Life of this patent
Estimating the term…
Abstract
The invention provides culture platforms, cell media, and methods of differentiating pluriptent cells into hematopoietic cells. The invention further provides pluripotent stem cell-derived hematopoietic cells generated using the culture platforms and methods disclosed herein, which enable feed-free, monolayer culturing and in the absence of EB formation. Specifically, pluripotent stem cell-derived hematopoietic cell of this invention include, and not limited to, iHSC, definitive hemogenic endothelium, hematopoietic multipotent progenitors, T cell progenitors, NK cell progenitors, T cells, and NK cells.
Claims11
An in vitro method for generating human pluripotent stem cell-derived T lineage cells comprising:
- contacting human pluripotent stem cell-derived pre-T cell progenitors with a composition comprising one or more growth factors and cytokines selected from the group consisting of SCF, Flt3L, and IL7, to obtain human pluripotent stem cell-derived T cell progenitors or T cells, wherein the composition is free of one or more of VEGF, bFGF, BMP activators and ROCK inhibitors;
- wherein the human pluripotent stem cell-derived pre-T cell progenitors are obtained by contacting human pluripotent stem cell-derived definitive hemogenic endothelium (HE) with a composition comprising a ROCK inhibitor, IL7, and one or more growth factors and cytokines selected from the group consisting of VEGF, bFGF, SCF, and Flt3L, to allow cell differentiation and expansion;
- wherein the human pluripotent stem cell-derived definitive hemogenic endothelium are obtained by contacting human pluripotent stem cell-derived mesodermal cells having definitive HE potential with a composition comprising a ROCK inhibitor, and one or more growth factors and cytokines selected from the group consisting of bFGF, VEGF, SCF, IL6 and IL11, to allow cell differentiation and expansion;
- wherein the composition is free of TGFβ receptor/ALK inhibitor;
- wherein the human pluripotent stem cell-derived mesodermal cells having definitive HE potential are obtained by contacting human pluripotent stem cell-derived mesodermal cells with a composition comprising a BMP activator, bFGF, and a GSK3 inhibitor, to allow cell differentiation and expansion, optionally wherein the composition is free of TGFβ receptor/ALK inhibitor, and
- wherein the human pluripotent stem cell-derived mesodermal cells are obtained by contacting human pluripotent stem cells with a composition comprising a BMP activator, and optionally bFGF, to allow cell differentiation and expansion.
Dependencies are inferred from the claim text.